Published in AIDS on May 02, 2003
Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol (2008) 3.04
Chronic HIV-1 infection frequently fails to protect against superinfection. PLoS Pathog (2007) 2.38
Retroviral superinfection resistance. Retrovirology (2005) 1.82
Evidence for frequent reinfection with human immunodeficiency virus type 1 of a different subtype. J Virol (2005) 1.77
Human immunodeficiency virus type 1 clade B superinfection: evidence for differential immune containment of distinct clade B strains. J Virol (2005) 1.77
The epidemiological impact of antiretroviral use predicted by mathematical models: a review. Emerg Themes Epidemiol (2005) 1.76
The origins of sexually transmitted HIV among men who have sex with men. Sci Transl Med (2010) 1.76
Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses. J Virol (2008) 1.73
Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. J Virol (2005) 1.68
Minority variants of drug-resistant HIV. J Infect Dis (2010) 1.44
Extensive intrasubtype recombination in South African human immunodeficiency virus type 1 subtype C infections. J Virol (2007) 1.37
Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate. J Virol (2009) 1.28
Identifying HIV-1 dual infections. Retrovirology (2007) 1.25
HIV-1 superinfection occurs less frequently than initial infection in a cohort of high-risk Kenyan women. PLoS Pathog (2013) 1.21
Frequency and implications of HIV superinfection. Lancet Infect Dis (2013) 1.19
HIV-1 superinfection in the antiretroviral therapy era: are seroconcordant sexual partners at risk? PLoS One (2009) 1.16
Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure. J Virol (2004) 1.15
Incidence and prevalence of intrasubtype HIV-1 dual infection in at-risk men in the United States. J Infect Dis (2013) 1.13
Timing and source of subtype-C HIV-1 superinfection in the newly infected partner of Zambian couples with disparate viruses. Retrovirology (2012) 0.95
Multiple HIV-1 infections with evidence of recombination in heterosexual partnerships in a low risk Rural Clinical Cohort in Uganda. Virology (2011) 0.93
Frequent intra-subtype recombination among HIV-1 circulating in Tanzania. PLoS One (2013) 0.92
Analysis of infectious virus clones from two HIV-1 superinfection cases suggests that the primary strains have lower fitness. Retrovirology (2010) 0.91
HIV-1 subtypes and recombinants in Northern Tanzania: distribution of viral quasispecies. PLoS One (2012) 0.87
Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients. J Clin Microbiol (2007) 0.86
Variability of HIV-1 genomes among children and adolescents from São Paulo, Brazil. PLoS One (2013) 0.85
Viral sequence analysis from HIV-infected mothers and infants: molecular evolution, diversity, and risk factors for mother-to-child transmission. Clin Perinatol (2010) 0.82
Transmitted HIV resistance to first-line antiretroviral therapy in Lima, Peru. AIDS Res Hum Retroviruses (2011) 0.81
Dynamics of HIV type 1 recombination following superinfection. AIDS Res Hum Retroviruses (2013) 0.80
Select resistance-associated mutations in blood are associated with lower CSF viral loads and better neuropsychological performance. Virology (2009) 0.79
Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort. BMC Infect Dis (2013) 0.78
Evidence for preferential genotyping of a minority human immunodeficiency virus population due to primer-template mismatching during PCR-based amplification. J Clin Microbiol (2005) 0.77
Two cases of possible transmitted drug-resistant HIV: likely HIV superinfection and unmasking of pre-existing resistance. Int J STD AIDS (2015) 0.75
HIV migration between blood plasma and cellular subsets before and after HIV therapy. J Med Virol (2015) 0.75
Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A (2003) 12.75
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med (2002) 10.03
Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med (2002) 9.70
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 7.49
The DNA sequence of the human X chromosome. Nature (2005) 6.97
Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis (2008) 6.43
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis (2008) 5.20
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis (2003) 4.51
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol (2003) 4.49
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol (2005) 4.35
Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med (2013) 4.26
Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother (2006) 4.14
Evidence for positive epistasis in HIV-1. Science (2004) 4.12
Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog (2013) 4.05
Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA (2002) 4.02
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A (2005) 3.94
Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis (2005) 3.93
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74
Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med (2008) 3.66
2011 update of the drug resistance mutations in HIV-1. Top Antivir Med (2011) 3.66
Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med (2013) 3.58
Highly precise measurement of HIV DNA by droplet digital PCR. PLoS One (2013) 3.53
Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med (2009) 3.52
HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A (2008) 3.40
Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol (2004) 3.20
Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med (2006) 3.06
Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol (2008) 3.04
Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis (2010) 2.98
Update of the Drug Resistance Mutations in HIV-1. Top HIV Med (2008) 2.91
Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med (2010) 2.91
Fld1p, a functional homologue of human seipin, regulates the size of lipid droplets in yeast. J Cell Biol (2008) 2.85
Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol (2005) 2.83
Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis (2013) 2.82
Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med (2007) 2.79
Evaluation of an HIV nucleic acid testing program with automated Internet and voicemail systems to deliver results. Ann Intern Med (2010) 2.69
A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase. Nat Genet (2011) 2.66
Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis (2003) 2.54
Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem (2003) 2.52
Adaptation to different human populations by HIV-1 revealed by codon-based analyses. PLoS Comput Biol (2006) 2.48
ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler Thromb Vasc Biol (2005) 2.46
Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. J Virol (2006) 2.33
Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis (2003) 2.30
Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis (2006) 2.26
Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother (2002) 2.21
HIV superinfection. J Infect Dis (2005) 2.20
Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol (2009) 2.19
Whither or wither microbicides? Science (2008) 2.17
Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol (2007) 2.14
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet (2013) 2.11
Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis (2008) 2.08
Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. Virology (2006) 2.07
Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog (2013) 2.06
Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects. AIDS (2003) 2.05
Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med (2005) 2.04
Role of seminal shedding of herpesviruses in HIV Type 1 Transmission. J Infect Dis (2012) 1.99
Neurocognitive and motor deficits in HIV-infected Ugandan children with high CD4 cell counts. Clin Infect Dis (2012) 1.97
Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance. AIDS (2003) 1.96
Statins inhibit synthesis of an oxysterol ligand for the liver x receptor in human macrophages with consequences for cholesterol flux. Arterioscler Thromb Vasc Biol (2004) 1.92
Incidence of HIV superinfection following primary infection. JAMA (2004) 1.92